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A B S T R A C T
Valproic acid (VPA) is widely used for the treatment of epilepsy, migraine, and a variety of psychiatric symp-
toms, including bipolar disorder, borderline personality disorder, and alcohol withdrawal. Valproate is asso-
ciated with severe idiosyncratic adverse effects, the most notable being valproate-induced hyperammonemic
encephalopathy (VHE). Topiramate is also a broad-spectrum anticonvulsant that is also extensively used for
migraine prophylaxis, as a mood stabilizer, and for alcohol dependency. There is increased occurrence of VHE
when valproate is used with other medications like phenytoin, phenobarbital, and topiramate. Our case report is
on a young patient who was on valproic acid and topiramate and developed metabolic encephalopathy with
hypoxic respiratory failure. We reviewed the causes and management of the hyperammonemic encephalopathy.
We believe that clinicians should be aware of possible hyperammonemic encephalopathy in any patient who is
taking valproic acid and presenting with impaired consciousness and cognitive decline. We also underline the
importance of early recognition and high index of suspicion of encephalopathy related to hyperammonemia.
1. Introduction
Valproic acid is a broad-spectrum antiepileptic drug that inhibits
degradation, and promotes postsynaptic transmission of gamma-ami-
nobutyric acid (GABA) [1]. Valproic acid (VPA) is widely used for the
treatment of epilepsy, migraine, and a variety of psychiatric symptoms,
including bipolar disorder, borderline personality disorder, and alcohol
withdrawal. VPA has been used effectively to reduce agitation and
aggression in both acute and post-acute traumatic brain injury patients,
as well as a variety of other neuropsychiatric syndromes, including
dementia and mental retardation [2–4]. Valproate is associated with
severe idiosyncratic adverse effects, the most notable being valproate-
induced hyperammonemic encephalopathy (VHE), which is seen in up
to 0.9% of patients taking valproate [5]. Topiramate is also a broad-
spectrum anticonvulsant that is also extensively used for migraine
prophylaxis, as a mood stabilizer, and for alcohol dependency. There
are studies in the literature which has shown an increased occurrence of
VHE when valproate is used with other medications like phenytoin,
phenobarbital, and topiramate [6].
The combined antiepileptic valproate and topiramate therapy
causes reduction of topiramate metabolism through cytochrome P 450
pathway and topiramate decreases levels of valproate by increasing its
metabolism [7].
VHE causes metabolic encephalopathy which is defined as a diffuse
cerebral dysfunction, typically manifesting as changes in cortical
functions and as disorders of consciousness, ranging from confusion to
coma [8].
Recognition of VHE requires a high level of clinical suspicion, as
clinical presentation is nonspecific and correlates poorly with dosage,
blood levels, or duration of treatment [9].
The development of hyperammonemia, the consequences of which
are difficult to differentiate from the pathology itself and that can be
misdiagnosed as therapeutic failure instead of an adverse drug reaction
related to the use of VPA [10].
This case report illustrates the importance high clinical suspicion
and early recognition of VHE and its management.
2. Case report
Our patient is a 21-year-old female patient with past medical history
of medically refractory epilepsy, hypothyroidism and mood disorder
came with altered mental status. She started to have seizure disorder
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from childhood and she was not eating and drinking because of her
clinical condition. She was also not taking her medications for the last 3
days. She underwent vagal nerve stimulation procedure for her epilepsy
and she was on Levetiracetam, Valproic acid and topiramate. She still
had seizures even if she is on these treatments but her mood disorder
was well controlled. Last seizure episode happened a month ago. She
was also having cough and mild shortness of breath but no fever or
chills. She is not a smoker and lives with her mother who takes care of
her. In the emergency room, she was found to be tachycardic and hy-
poxic with a PH of 7.37, PCO2 of 39 and PO2 of 56 on arterial blood
gas. CT chest performed there showed bilateral lung infiltrates sug-
gestive of pneumonia. On physical examination, blood pressure was
124/86, heart rate was 107 beats per minute, respiratory rate was 19
breaths per minute and temperature was 99.2-degree fahrenheit. Well
developed, well-nourished but limited spontaneous speech, mild con-
fusion. Scattered soft crepitations in the lower posterior chest bilat-
erally and has regular rate and rhythm of the pulse with no murmur and
no gallop. She didn't have any edema. On neurologic examination, she
was alert, follows some specific commands and names simple objects.
She had no gaze preference and facial strength and sensation were in-
tact and symmetric. Neck was supple with no neck stiffness. Hearing
was grossly intact and symmetric. Strength was 5/5 in all 4 extremities
without evidence of pronator drift. She had intact sensation to light
touch and pin prick sensation in all her extremity without evidence of
asymmetry. She had no evidence of dysmetria with finger to nose bi-
laterally. She was admitted to a step-down unit and she was started on
broad spectrum antibiotics and maintenance intravenous fluids. Her
antiepileptic medications were also restarted at the same dose that she
was getting at home. Her procalcitonin and lactic acid levels were
found to be with in normal range. Atypicals and viral panel were found
to be negative and blood and sputum culture were negative. Antibiotics
were deescalated accordingly. On the next day of admission, patient
was still having mild confusion and ammonia level was ordered and it
was found to be elevated at 102 μg/deciliter (mcg/dl). Her valproic acid
level in the same day was 77 mcg/dl (normal 50–125 mcg/dl). Her TSH
level was within the normal limit. At this point, metabolic encephalo-
pathy due to hyperammonemia was considered and she was started on
L-carnitine and Lactulose. Patient's clinical condition stayed the same
with this treatment.
Her ammonia level increased to 126 mcg/dl. EEG was performed
and reported to show intermittent generalized slowing consistent with a
mild encephalopathy but there were no electroencephalographic sei-
zures or any interictal epileptiform activity. The cause of the hyper-
ammonemia was thought to be related to valproic acid. Her epilepsy
was relatively well controlled by her seizure medications and there was
a reluctance to stop any of her medications from the primary team.
Neurology evaluation suggested decreasing the dose of topiramate
as it was a relatively new medication. Her topiramate dose was halved
and was continued with L- Carnitine and lactulose but her confusion
stayed the same and her ammonia level on the next day increased to
162. Her repeat valproic acid level was 77 mcg/dl. Since there was no
clinical improvement with the treatment, valproic acid was stopped.
The clinical condition of the patient improved day by day after that and
her ammonia level was trended daily and it came down from 161 to 115
mcg/dl at first and within 3 days it went down to 52 mcg/dl. Five days
after valproic acid was stopped, patient's clinical condition stabilized
and her seizure medications were changed to Levetiracetam and laco-
samide. She was not having any seizure activity and her mood disorder
stayed stable and her general condition got back to her baseline.
3. Discussion
In one report, it is estimated that up to 50% of patients taking
valproate develop hyperammonemia. Most of these patients have ele-
vations of ammonia with normal liver function and are asymptomatic
[11,12]. There is also no clear correlation between blood ammonia
levels and the severity of encephalopathy, suggesting that mechanisms
other than those involving ammonia contribute to the neurological
dysfunction [1]. Approximately 0.9% of patients using valproate de-
velop hyperammonemic encephalopathy. This number could be higher
if patients are taking sedatives and other antiepileptic medications like
lamotrigine, topiramate and risperidone [13]. Carnitine deficiency and
urea cycle enzyme abnormalities also expose patients for valproate and
topiramate induced hyperammonemic encephalopathy [2–4]. Our pa-
tient was on topiramate in addition to the valproic acid but she was not
checked for carnitine deficiency or urea cycle enzyme defect. Topir-
amate was originally synthesized as a potential hypoglycemic agent
even if it was found not to have that effect and it was later found out
that it is an important medication for seizure, migraine prophylaxis and
mood disorder due to its effect in the CNS and sodium and calcium
channels [5,6]. The presence of pneumonia in our patient might be
responsible for her deterioration and presentation to us but her clinical
response with the decrease in the level of the ammonia supports the fact
that the hyperammonemia is responsible for her deterioration.
The mechanism by which valproate causes hyperammonemia is not
clear but hepatic and renal metabolic pathways have been proposed.
Propionate, a metabolite of valproate reduces hepatic N-acet-
ylglutamate concentration, which is an obligatory activator of carba-
moyl phosphate synthetase 1 (CPS-1), the first enzyme of the urea cycle.
Decline in CPS-1 activity results in defective ammonia utilization and
accumulation of ammonia. Another mechanism thought to play a role is
reduction of hepatic carnitine levels by valproate. This results in de-
creased beta-oxidation of fatty acids, which in turn results in reduced
levels of Acetyl Co-A. This decrease in Acetyl Co-A ultimately disrupts
the urea cycle resulting in ammonia accumulation [2]. The less
common mechanism is that valproic acid stimulates kidney tubule
glutaminase that subsequently enhances glutamine uptake into renal
cortical cell mitochondria. The conversion of glutamine ultimately
leads to increased ammonia production [4]. The cytosolic ammonia
accumulated within astrocytes and neuronal cells which is conjugated
with glutamine by glutamine synthetase is responsible for the oxidative
stress and subsequently leads to mitochondrial swelling and cytosolic
edema [2,14]. Availability of electroencephalogram recordings may
help improve diagnostic validity, but it is unlikely to facilitate differ-
entiation of VPA from other causes of encephalopathy [13].
We have EEG recordings done in our patient which showed inter-
mittent generalized slowing consistent with a mild encephalopathy but
there were no electroencephalographic seizures or any interictal epi-
leptiform activity. Our patient could possibly have a non-convulsive
seizure due to drug withdrawal with subsequent deterioration since she
was not taking her medications for 3 days before presentation. This is
very difficult to prove as we only have EEG 2 days after her presenta-
tion.
The mainstay of VHE treatment is discontinuation of VPA, which
leads to complete recovery in most patients [1–4]. We decreased the
dose of both valproate and topiramate in our patient but patient's
clinical condition didn't improve. So, both medications were stopped
and she was started on L-carnitine. Persistence of VHE despite reduction
or discontinuation of VPA is an indication for additional ammonia-de-
pleting agents such as lactulose, charcoal, neomycin, rifaximin, or L-
carnitine [2,3]. We have used L-carnitine and lactulose in our patient
since discontinuation of the medications didn't completely improve her
clinical condition. L-carnitine is an amino acid derivative and important
nutrient involved in fat metabolism. Up to 75% of L-carnitine is pro-
vided by diet, particularly red meat and dairy products. It is also bio-
synthesized endogenously from dietary amino acids (methionine, ly-
sine), especially in the liver and in the kidneys. Carnitine is responsible
for 2 metabolic functions. It eases the fatty acyl-group transport into
mitochondria and it also preserves the ratio of acyl-CoA to free CoA in
the mitochondria.
As VPA-induced hyperammonemia and VHE could be mediated at
least in part by carnitine deficiency, it has been hypothesized that L-
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carnitine supplementation may prevent, correct, or attenuate these
adverse effects [5–9]. L-carnitine should be given intravenously because
of the low bioavailability of enteral L-carnitine [7]. There is also a lit-
erature on the use of arginine supplementation for treatment of hy-
perammonemic encephalopathy even if we haven't used it in our pa-
tient. Arginine supplementation tends to normalize elevated plasma
ammonia concentrations. Arginine plays a critical role in ammonia
detoxification, as ammonia is detoxified via its metabolism into urea.
On the one hand, it has been accepted that arginine is an activator of N-
acetyl glutamate synthetase (NAGS) via agmatine; on the other hand,
arginine entering the liver via the portal vein is metabolized to provide
ornithine for citrulline and aspartate synthesis and for the priming of
the urea cycle [6,10]. The clinical response of our patient was corre-
lated with the decrease in the serum ammonia level but literature has
shown that serum levels of ammonium do not correlate with the se-
verity of valproate-induced encephalopathy and there is no conclusive
evidence of a major causative role of hyperammonemia on en-
cephalopathy in human clinical studies [1–3]. Because of that it is
suggested to follow patients clinically rather than monitor the level of
serum ammonia once the diagnosis of hyperammonemic encephalo-
pathy was made and the right treatment started. The valproic acid level
of our patient stayed in the normal range the whole time in our patient
but still there is no concordance with respect to a direct relationship
between the development of VHE and serum valproic acid levels [2–5].
4. Conclusion
Metabolic encephalopathy represents a serious problem that needs
to be addressed in a multidisciplinary approach as there could be
complications related to the respiratory and central nervous system. We
need to have a high index of suspicion for diagnosing VHE in patients
receiving valproate presenting with impaired consciousness and acute
cognitive decline. Serum ammonia level is a useful test to guide in di-
agnosing VHE but it is very important to know that its level does not
correlate with the severity of VHE. Increased familiarity with the di-
agnosis and appropriate treatment of VHE is also essential. Resolution
or prevention of hyperammonemia may be enhanced with the admin-
istration of intravenous L-carnitine as the oral form has low bioavail-
ability.
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